On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Up for PAFSC Review on Oct. 30
October 19, 2020
- Japan’s Conditional Approval System for Regenerative Meds Is “Patient-Centered System”: PMDA Exec
October 19, 2020
- Japan Needs to Consider Legal Positioning of Stable Drug Supply Rules: Official
October 19, 2020
- LDP’s Health Committee OKs Bill to Amend Immunization Act
October 16, 2020
- Forxiga’s Heart Failure Use Up for PAFSC Discussion on October 29
October 16, 2020
- PMDA Gets Nearly 10 Requests for Free COVID-19 Vaccine Consultations in 2 Weeks
October 15, 2020
- MHLW to Make “Comprehensive Decision” on Off-Year Drug Pricing Plan: Minister
October 15, 2020
- MHLW Revises Leaflets on HPV Vaccination, Issues Related Notification
October 13, 2020
- Make Temporary Measure Permitting Telemedicine Permanent: Reform Panel Members
October 12, 2020
- MHLW to Reexamine Whether to Permit Sale of Emergency Contraceptives Without a Prescription
October 12, 2020
- Opdivo under PMDA Risk Review for Fulminant Hepatitis
October 12, 2020
- List of MOF’s Proposals Related to Pharmaceuticals
October 9, 2020
- MOF Calls for Setting New Targets for Generic and Biosimilar Use
October 9, 2020
- MHLW to Revise Immunization Act to Allow Govt to Shoulder Liability Risks for COVID-19 Vaccines
October 9, 2020
- MOF Pitches Off-Year Re-Pricing for “All Products” Including Patented Meds, Eyes Adjustment Rate Revision Too
October 9, 2020
- CEFP Members Call for Tapping CPTPP Trade Deal for Joint Drug Manufacturing
October 8, 2020
- Elite Team Working to Secure COVID-19 Vaccines; Indemnity to Be a Major Focus: Ex-MHLW Chief Medical Officer
October 8, 2020
- Japan’s COVID-19 Vaccine, Drug Development Lack Speed: Ex-MHLW Chief Medical Officer
October 7, 2020
- Health Minister Denies November Plan for Avigan's COVID-19 OK
October 7, 2020
- MHLW Panel Approves 18th Edition of Japanese Pharmacopoeia; 33 New Products Added
October 7, 2020
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…